-
Mashup Score: 0Zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström’s macroglobulinemia - 3 year(s) ago
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, compares the efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in patients…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of BTK inhibitors in the management of Waldenström’s…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New Treatment Options for Waldenstrom Macroglobulinemia - 3 year(s) ago
Waldenstrom macroglobulinemia expert shares news on promising drug combinations to treat the disease.
Source: Patient PowerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Watch and Wait for Waldenstrom Macroglobulinemia - 3 year(s) ago
Waldenstrom macroglobulinemia is sometimes over-treated. When is “watch and wait” the best option for this chronic disease?
Source: Patient PowerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Jorge Castillo of @DanaFarber talks on the efficacy and safety of zanubrutinib vs rituximab-based chemoimmunotherapy in #WaldenstromsMacroglobulinemia 👨⚕️ Watch here 👉https://t.co/A6N2P3FFaR👈 @EHA_Hematology #EHA2021 @VJHemOnc #HemOnc #Lymphoma #LYMsm #WMsm #Waldenstroms